Stefano Boschi1, Jason T Lee2, Seval Beykan3, Roger Slavik4, Liu Wei4, Claudio Spick4, Uta Eberlein3, Andreas K Buck3, Filippo Lodi1, Gianfranco Cicoria5, Johannes Czernin4, Michael Lassmann3, Stefano Fanti1, Ken Herrmann6,7. 1. Department of Nuclear Medicine, S.Orsola-Malpighi University Hospital, Via Massarenti 9, 40138, Bologna, Italy. 2. Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, USA. 3. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. 4. Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave. CHS AR-255, Los Angeles, CA, 90095, USA. 5. Department of Medical Physics, S. Orsola-Malpighi University Hospital, Bologna, Italy. 6. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. KHerrmann@mednet.ucla.edu. 7. Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave. CHS AR-255, Los Angeles, CA, 90095, USA. KHerrmann@mednet.ucla.edu.
Abstract
PURPOSE: The aim of this study was to synthesize and preclinically evaluate an 18F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined. METHODS: Several conditions for the labeling of 18F-PSMA-11 via 18F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed. RESULTS: Quantitative labeling yields could be achieved with >97 % radiochemical purity. The 18F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv. CONCLUSION: 18F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.
PURPOSE: The aim of this study was to synthesize and preclinically evaluate an 18F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined. METHODS: Several conditions for the labeling of 18F-PSMA-11 via 18F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed. RESULTS: Quantitative labeling yields could be achieved with >97 % radiochemical purity. The 18F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv. CONCLUSION:18F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.
Entities:
Keywords:
18F; Dosimetry; PET; PSMA; Preclinical; Prostate cancer
Authors: Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper Journal: Clin Cancer Res Date: 2011-10-31 Impact factor: 12.531
Authors: William J McBride; Christopher A D'Souza; Habibe Karacay; Robert M Sharkey; David M Goldenberg Journal: Bioconjug Chem Date: 2012-02-10 Impact factor: 4.774
Authors: Ali Afshar-Oromieh; Henrik Hetzheim; Clemens Kratochwil; Martina Benesova; Matthias Eder; Oliver C Neels; Michael Eisenhut; Wolfgang Kübler; Tim Holland-Letz; Frederik L Giesel; Walter Mier; Klaus Kopka; Uwe Haberkorn Journal: J Nucl Med Date: 2015-08-20 Impact factor: 10.057
Authors: Christian Uprimny; Alexander Kroiss; Bernhard Nilica; Sabine Buxbaum; Clemens Decristoforo; Wolfgang Horninger; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2014-10-08 Impact factor: 9.236
Authors: Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum Journal: Eur Urol Date: 2015-06-25 Impact factor: 20.096
Authors: Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Heike Endepols; Agnieszka Morgenroth; Boris D Zlatopolskiy; Philipp Krapf; Johannes Zischler; Raphael Richarz; Sergio Muñoz Vásquez; Bernd Neumaier; Felix M Mottaghy Journal: BMC Cancer Date: 2019-06-26 Impact factor: 4.430
Authors: Gordon Winter; Andrea B F Koch; Jessica Löffler; Mika Lindén; Christoph Solbach; Alireza Abaei; Hao Li; Gerhard Glatting; Ambros J Beer; Volker Rasche Journal: Cancers (Basel) Date: 2020-05-15 Impact factor: 6.639
Authors: Sarah Piron; Jeroen Verhoeven; Benedicte Descamps; Ken Kersemans; Kathia De Man; Nick Van Laeken; Leen Pieters; Anne Vral; Christian Vanhove; Filip De Vos Journal: Sci Rep Date: 2020-12-03 Impact factor: 4.379
Authors: Sarah Piron; Kathia De Man; Vanessa Schelfhout; Nick Van Laeken; Ken Kersemans; Eric Achten; Filip De Vos; Piet Ost Journal: EJNMMI Res Date: 2020-02-24 Impact factor: 3.138
Authors: Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe Journal: Theranostics Date: 2020-01-01 Impact factor: 11.556